Posted: JUN 5, 2008

CSMG Technologies Comments on Importance of Live Tissue Connect Completing Key Onsite Audit; Milestone towards Achieving CE Mark Registration

Corpus Christi, TX, June 5, 2008 -- CSMG Technologies, Inc., (OTCBB: CTGI - News), a technology management company, announced that its Live Tissue Connect ("LTC") subsidiary completed the onsite audit portion of the CE Mark registration in accordance with the European Medical Device Directive - 93/42/EEC. LTC announced it has already received its ISO 13485:2003 certification for the design and manufacture of Bipolar Forceps Systems. This Quality Management System certificate was issued by BSI Management Systems, one of the world's leading certification bodies.

Donald S. Robbins, President and CEO of CSMG Technologies, said, "We are very pleased to have successfully completed the onsite audit last month. As we progress through this process towards achieving CE Mark in the Europe, the LTC team is currently researching marketing and sales channels."

Frank D'Amelio, President of LTC, stated, "Passing the onsite audit marks the second of three critical milestones towards achieving the CE Mark for LTC's Bipolar Sealing Forceps. The first step was the receipt of our ISO 13485:2003 Quality System Certification in March, 2008. The CE Mark is a requirement for the sale of medical devices in the European Union."

About Live Tissue Connect

LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 31 patents in the U.S., Australia, Canada, European Union, Ukraine and other countries.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: www.csmgtechinternational.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CONTACT:

CSMG Technologies, Inc.
Donald S. Robbins, 361-887-7546
President and CEO
or
K. Bruce Jones, 770-955-0409